Results 231 to 240 of about 33,791,512 (292)

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Review Article: Fibrosis‐4 Index in Steatotic Liver Disease—Past, Present and Future

Alimentary Pharmacology &Therapeutics, EarlyView.
FIB‐4 remains an inexpensive, scalable first‐line triage tool for excluding advanced fibrosis and identifying patients who need second‐line assessment, but it should not be used as a stand‐alone diagnostic or treatment‐selection test. Sequential testing and longitudinal FIB‐4 trajectories may improve risk stratification and prognosis.
Kriti Soni, Vinay Jahagirdar, Omar Albhaisi, Richard K. Sterling, Juan Pablo Arab, Hanna Blaney, Luis Antonio Díaz   +6 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms. [PDF]

Fundam Clin Pharmacol
Eiden C, Chautard G, Batisse A, Aquizerate A, Luquiens A, Donnadieu H, Faillie JL, Peyriere H.   +7 more
europepmc   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review. [PDF]

Diabetes Obes Metab
Chan TH, Cosler LE, Gionfriddo MR, Leppien EE, Sommers EJ, Lussier ME.   +5 more
europepmc   +1 more source

Novel Compounds as Glucagon-Like Peptide‑1 Receptor Agonists for Treating Diabetes. [PDF]

ACS Med Chem Lett
Sabnis RW.
europepmc   +1 more source

Glucagon-Like Peptide-1 Targets in the Human Nodose Ganglion. [PDF]

J Comp Neurol
Merchant W, Mackaaij C, Cleypool CGJ, Gautron L.   +3 more
europepmc   +1 more source

Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025. [PDF]

Obesity (Silver Spring)
Kildegaard H, Andersen JH, Vinding RK, Kloppenborg JT, Pottegård A.   +4 more
europepmc   +1 more source